Abstract
Elevated urokinase-type plasminogen activator (uPA) expression in breast tumors predicts poor survival. We found celecoxib (25 microM) significantly reduced uPA protein and mRNA in MDA-MB-231 breast cancer cells following 72 h of treatment. Celecoxib also inhibited cell viability (12.5 and 25 microM) and induced G2M arrest (25 microM). Therefore, celecoxib therapy for uPA positive breast cancer should be explored.
Publication types
-
Evaluation Study
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Breast Neoplasms / drug therapy*
-
Celecoxib
-
Cell Line, Tumor
-
Cell Proliferation / drug effects
-
Cyclooxygenase Inhibitors / pharmacology*
-
Dose-Response Relationship, Drug
-
Humans
-
Mitogen-Activated Protein Kinase 1 / drug effects
-
Mitogen-Activated Protein Kinase 3 / drug effects
-
Proto-Oncogene Proteins c-akt / drug effects
-
Pyrazoles / pharmacology*
-
RNA, Messenger / drug effects
-
Signal Transduction / drug effects
-
Sulfonamides / pharmacology*
-
Urokinase-Type Plasminogen Activator / antagonists & inhibitors*
-
Urokinase-Type Plasminogen Activator / genetics
Substances
-
Cyclooxygenase Inhibitors
-
Pyrazoles
-
RNA, Messenger
-
Sulfonamides
-
Proto-Oncogene Proteins c-akt
-
Mitogen-Activated Protein Kinase 1
-
Mitogen-Activated Protein Kinase 3
-
Urokinase-Type Plasminogen Activator
-
Celecoxib